Article
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
American journal of hematology - 1 Oct 2023
Haddad Fadi G, Sasaki Koji, Bidikian Aram, Issa Ghayas C, Kadia Tapan, Jain Nitin, Alvarado Yesid, Short Nicholas J, Pemmaraju Naveen, Loghavi Sanam, Patel Keyur P, Kanagal-Shamanna Rashmi, Yilmaz Musa, Masarova Lucia, Jabbour Elias, Kantarjian Hagop
Abstract excerpt
Patients with chronic myeloid leukemia (CML) and T315I mutation generally have a poor prognosis. Their outcome in the post-ponatinib era remains unclear. We reviewed patients with CML in chronic (CP) or accelerated phase (AP) who developed a T315I mutation between March 15, 2004, and July 26, 2022. Patients were divided into CP, AP, or blastic phase (BP) at the time of mutation detection. Overall survival (OS)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.